ReviewPathogens (Basel, Switzerland)2023
Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses.
Review in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Research trends in Rift Valley fever virus: a bibliometric analysis from 1936 to 2024.Frontiers in veterinary science · 2025Pooled it
- Pathogenicity of Rift Valley fever virus: Organ-specific clinical outcomes and hidden drivers of virulence - a narrative review.Virulence · 2026Review
- Differential innate immune activation by wild-type and NSs-deficient RVFV strains in human blood monocytes.Emerging microbes & infections · 2026Article
- Induction of a Th1-Type Polyfunctional T-Cell Response by the Four-segmented Rift Valley Fever Candidate Vaccine in Humans.The Journal of infectious diseases · 2026Article
- Climate Change, Urbanization, and the Emerging Urban Threat of Rift Valley Fever in Tropical and Subtropical Cities: A Narrative Review.Tropical medicine and infectious disease · 2026Review
- Efficient Sensing of a 4-Segmented Rift Valley Fever Virus Vaccine Candidate by Human Monocytes.The Journal of infectious diseases · 2026Article
- Immunopharmacologsical and structural insights into Rift Valley fever virus envelope glycoproteins: an immunoinformatics approach to multi-epitope vaccine design.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health.Vaccines · 2026Review
- Evolutionary dynamics and molecular adaptation of Rift Valley fever virus across human and non-human outbreaks in Africa.BMC genomics · 2026Article
- Intranasal infection of Rift Valley fever virus in the ferret model suggests multiple routes of neuroinvasion with consequential encephalitis and ophthalmitis.Scientific reports · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Review
- Article
- Incidence rate of Rift Valley fever exposure in humans and livestock from a longitudinal study in Northern Kenya.Scientific reports · 2025Article
- Article
- Climate change and the emergence of Rift Valley fever virus: a pathological and environmental study of sheep jaundice in Egyptian slaughterhouses.BMC veterinary research · 2025Article
- Rift Valley fever virus and Coxiella burnetii infections among febrile patients, Eastern Ethiopia.PLoS neglected tropical diseases · 2025Article
- The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.Viruses · 2025Review
- Rift Valley fever: A zoonotic disease with global potential.Open veterinary journal · 2025Review
- A DNA vaccine candidate provides protection against Rift Valley Fever virus in sheep under natural field conditions.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Rift Valley Fever Virus is a mosquito-borne phlebovirus causing febrile or haemorrhagic illness in ruminants and humans. The virus can prevent the induction of the antiviral interferon response through its NSs proteins. Mutations in the NSs gene may allow the induction of innate proinflammatory immune responses and lead to attenuation of the virus. Upon infection, virus-specific antibodies and T cells are induced that may afford protection against subsequent infections. Thus, all arms of the adaptive immune system contribute to prevention of disease progression. These findings will aid the design of vaccines using the currently available platforms. Vaccine candidates have shown promise in safety and efficacy trials in susceptible animal species and these may contribute to the control of RVFV infections and prevention of disease progression in humans and ruminants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.